Business Segments (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Summary of segmental information

	Three Months Ended September 30,
	2012			2011
Revenues
Vaccines/BioDefense	$	862,919		$	581,943
BioTherapeutics		68,708			5,213,919
Total	$	931,627		$	5,795,862
(Loss) Income from Operations
Vaccines/BioDefense	$	19,190		$	5,869
BioTherapeutics		(155,713	)		2,684,937
Corporate		(623,693	)		(487,343	)
Total	$	(760,216	)	$	2,203,463
Amortization and Depreciation Expense
Vaccines/BioDefense	$	31,357		$	11,247
BioTherapeutics		32,180			47,791
Corporate		495			559
Total	$	64,032		$	59,597
Interest Income, Net
Corporate	$	1,250		$	1,411
Stock-Based Compensation
Vaccines/BioDefense	$	29,103		$	16,998
BioTherapeutics		(49,275	)		60,487
Corporate		167,944			63,668
Total	$	147,772		$	141,153

	Nine Months Ended September 30,
	2012			2011
Vaccines/BioDefense	$	2,170,761		$	1,453,558
BioTherapeutics		171,135			5,556,129
Total	$	2,341,896		$	7,009,687
(Loss) Income from Operations
Vaccines/BioDefense	$	(111,319	)	$	5,921
BioTherapeutics		(1,363,572	)		(359,792	)
Corporate		(1,707,992	)		(1,098,302	)
Total	$	(3,182,883	)	$	(1,452,173	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	84,308		$	31,119
BioTherapeutics		86,913			132,282
Corporate		1,564			1,641
Total	$	172,785		$	165,042
Interest Income, Net
Corporate	$	5,284		$	5,319
Stock-Based Compensation
Vaccines/BioDefense	$	33,363		$	53,830
BioTherapeutics		63,339			346,995
Corporate		286,072			128,963
Total	$	382,774		$	529,788

	As of September 30,  2012		As of December 31, 2011
Identifiable Assets
Vaccines/BioDefense	$	556,020	$	689,266
BioTherapeutics		595,220		753,767
Corporate		3,921,820		6,780,625
Total	$	5,073,060	$	8,223,658